Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human TP53/p53 Antibody (163.6#)

Catalog #:   RHC10005 Specific References (49) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, WB
Expression system: Mammalian Cells
Overview

Catalog No.

RHC10005

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

TP53, Cellular tumor antigen p53, Tumor suppressor p53

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P04637

Applications

ELISA, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

163.6#

Data Image
References

The Intrabody Against Murine Double Minute 2 via a p53-Dependent Pathway Induces Apoptosis of Cancer Cell., PMID:40508092

High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies., PMID:40497952

Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331

Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma?, PMID:40448797

Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1-Mutated Metastatic Lung Adenocarcinoma., PMID:40448514

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758

B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies., PMID:40435909

Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001

Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma., PMID:40403397

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer., PMID:40393272

Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198

Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression., PMID:40379141

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510

FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates., PMID:40344965

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919

PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer., PMID:40273724

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer., PMID:40239138

Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine., PMID:40237885

Bioconjugates of photon-upconversion nanoparticles with antibodies for the detection of prostate-specific antigen and p53 in heterogeneous and homogeneous immunoassays., PMID:40231544

Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma., PMID:40215977

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma., PMID:40204067

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272

Pancreatic Cancer: Pathogenesis and Clinical Studies., PMID:40182139

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms., PMID:40168773

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580

[Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]., PMID:40159024

Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond., PMID:40146175

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review., PMID:40127387

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422

Fc fragment of IgG binding protein suppresses tumor growth by stabilizing wild type P53 in colorectal cancer cells., PMID:40108539

Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges., PMID:40105906

Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes., PMID:40080442

Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy., PMID:40066747

Case Report: Complete response to four cycles of camrelizumab in a PD-L1 negative patient with advanced oral squamous cancer., PMID:40066447

Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies., PMID:40045912

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334

Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)., PMID:40036771

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma., PMID:40030008

Gastric-type endocervical adenocarcinoma, superficial myofibroblastoma, sex cord-stromal tumors, and HSIL in Peutz-Jeghers syndrome: a rare case report, genetic characterization, and review of literature., PMID:40018404

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents., PMID:40011029

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study., PMID:40009500

An Anti-CD147 Antibody-Drug Conjugate Mehozumab-DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey., PMID:39985225

miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia., PMID:39976417

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432

Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma., PMID:39939142

A high sensitivity assay of UBE3A ubiquitin ligase activity., PMID:39933617

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054

Immunolipid magnetic bead-based circulating tumor cell sorting: a novel approach for pathological staging of colorectal cancer., PMID:39927117

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human TP53/p53 Antibody (163.6#) [RHC10005]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only